Medtronic plc - MDT STOCK NEWS

GE Healthcare and Medtronic have announced a collaboration aimed at enhancing care in Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs). This partnership will provide customers with access to a broad range of products, financial solutions, and services. The COVID-19 pandemic has shifted many procedures to outpatient settings, and this trend is expected to grow. The collaboration seeks to address the high costs and complexities associated with expanding ASCs, offering consultative planning and advanced technologies. GE Healthcare's Edison-powered imaging solutions are highlighted as a key offering.

Medtronic and GE Healthcare have announced a collaboration to enhance outpatient care at Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs). This partnership aims to address the growing demand for outpatient procedures, fueled by the COVID-19 pandemic and rising disease rates. As CMS approved cardiovascular payments in 2020, the use of fixed c-arm imaging systems has surged in these settings. The collaboration will provide extensive product portfolios, financial solutions, and services to improve workflow and clinical outcomes in outpatient environments.

Medtronic has appointed Dr. Laura Mauri as Chief Scientific, Medical and Regulatory Officer, effective April 25, 2022. This role expands her prior responsibilities and aims to unify the company’s medical and scientific efforts. Dr. Mauri's priorities include enhancing patient safety and engagement, aided by the recent hiring of Dr. Olaf Hedrich as Chief Medical Safety Officer. Joining Medtronic in September 2018, Dr. Mauri has significantly impacted trial design and regulatory advancements. She succeeds Dr. Richard Kuntz, who retires on April 29, 2022.

Medtronic plc (NYSE:MDT) has presented long-term data from the SPYRAL HTN-ON MED trial at the American College of Cardiology's ACC.22 session, demonstrating significant blood pressure reductions achieved through its Symplicity Spyral Renal Denervation (RDN) System. In the first 80 patients, the RDN group showed a reduction of 18.7 mmHg in 24-hour systolic blood pressure after three years compared to 8.6 mmHg in the sham group. Additionally, procedural safety was confirmed with no major adverse events reported. The study aims to support the RDN system's regulatory approval in the U.S.

Medtronic Australasia has selected Alimetry and The Clinician as winners of the inaugural Medtronic APAC Innovation Challenge (MAIC). This challenge received over 320 applications from 46 countries, showcasing regional healthcare innovations. Winners gain collaboration opportunities with Medtronic, including funding for commercialization efforts valued at up to US$200,000. The initiative, launched in October 2021, aims to foster local innovations addressing healthcare challenges in the APAC region.

Medtronic plc (NYSE: MDT) announced the commencement of the TITAN 2 pivotal study, focusing on the implantable tibial neuromodulation (TNM) device intended to treat overactive bladder (OAB). The first patient implants were completed, marking a significant step towards expanding access to advanced bladder incontinence therapies. This minimally invasive device aims to stimulate the posterior tibial nerve, potentially improving patient convenience and treatment options. The study will involve 130 patients across 30 U.S. sites, with follow-ups extending to 24 months.

Medtronic announced key leadership transitions for its Diabetes, Surgical Robotics, and Cardiac Rhythm Management units as of March 17, 2022. Que Dallara joins as EVP & President, Diabetes, leveraging her experience from Honeywell and Microsoft. Mike Marinaro steps in as President, Surgical Robotics, after leading a $4 billion annualized revenue segment. Dr. Kweli Thompson takes the role of President, Cardiac Rhythm Management, aiming to enhance growth and profitability. These changes are expected to strengthen Medtronic's market position and attract world-class talent.

Medtronic's GI Genius intelligent endoscopy module demonstrates improved polyp detection during colonoscopy, according to findings published in Gastroenterology. The study revealed a 50% reduction in adenoma miss rates when using GI Genius compared to standard techniques (15.5% vs 32.4%; p < 0.001). Additionally, false negative rates decreased significantly (6.8% vs 29.6%). Conducted across multiple centers, the study involved 249 participants, emphasizing AI's role in enhancing colorectal cancer screening accuracy. Medtronic is the exclusive distributor of GI Genius, which has received U.S. FDA authorization.